When patients face a diagnosis of B-cell lymphoma or chronic lymphocytic leukemia, choosing the right treatment is a heavy decision. One major concern for many patients is whether certain medications might cause a second, different type of cancer over time. This is a common worry when starting long-term treatments for blood cancers.
Researchers looked at data from over 9,000 patients taking a class of drugs called BTK inhibitors. They specifically looked for signs of a second primary malignancy, which is just a medical way of saying a second primary cancer. The study found that the rate of these new cancers was about 8 percent. Most importantly, the risk did not significantly increase for patients taking these drugs compared to those who did not.
While the study found that the length of time a patient was followed was the only factor that predicted a new cancer, it did not show that the medication itself caused the problem. This helps clarify that these drugs do not have a direct carcinogenic effect, meaning they do not directly cause cancer. Patients and doctors can feel more confident in the safety profile of these specific treatments.
